First Indian study on Single shot Viscosupplementation establishes it as effective treatment for knee-osteoarthritis

Over 80% of the patients respond positively to the treatment at the end of 52 weeks

 

Indore:  Signaling relief to over 15 million knee-osteoarthritis patients in India, the world‘s first study “Osteoarthritis Synvisc One Indian Post Marketing Study” (OASIS) (1) has revealed positive results on the impact of single-shot Viscosupplementation therapy reducing knee pain in osteoarthritis patients.  The first of its kind OASIS findings are especially significant for Indians who have a propensity to suffer from arthritis due to our genetic makeup.

Knee-osteoarthritis is a condition in which the cartilage that acts as a cushion between bones, in joints, begins to wear out. This results in inflammation and pain in joints, thereby restricting movement.  Till a few years ago, it only impacted the older population but a growing reverse trend has resulted in more and more young people being diagnosed with this condition (2)

Viscosupplementation is a path-breaking treatment that uses a biological substance to lubricate and cushion the diseased knee joint enabling easy movement and increased flexibility.  The OASIS findings prove that single-shot Viscosupplementation therapy provides relief from pain for up to twelve months. It is especially effective when used in the initial stages of the disease thereby highlighting the need for timely diagnosis and treatment.

 

This pioneering study evaluated the efficacy and safety of Synvisc One in - 369 knee-osteoarthritis patients in the age group of 30 years and above across 36 hospitals in 14 different Indian cities.

 

According to an investigator of the study, Dr. Saket Jati, Consultant Orthopedic Surgeon and Professor, SAIMS Medical College and Hospital, Indore “The OASIS study has proved the effectiveness of single shot Viscosupplementation for the first time in India. Knee osteoarthritis affects 15 million Indians with an increasing number of patients belonging to the 30-50 age group. This is where early treatment through single shot Viscosupplementation can play a crucial role in decreasing knee pain amongst the patients and improving their quality of life. OASIS has shown that patients were able to resume their routine activities with minimal or no side effects."

 

 

Consider the following facts revealed during the course of the 52 week OASIS study:

 

Results: Out of 394 patients enrolled, 369 patients were evaluated at Week 52. The walking pain significantly decreased as early as Week 1 after the injection and was down by 45.7% at Week 26 and 53.1% at Week 52.

 

According to Dr. A.K. Jinsiwale, Consultant Orthopedic Surgeon,Indore“"Osteoarthritis; once considered a disease of the elderly, is affecting more and more young people inIndia. The reason for this can be attributed to lifestyle factors such as obesity, Vitamin-D deficiency, poor diet and a sedentary lifestyle. Until now, knee osteoarthritis patients were dependent on painkillers for temporary relief from knee pain. However with the success of single shot Viscosupplementation as established by the OASIS study, a large majority of the patients can get relief from knee pain for up to 12 months in just one injection. Viscosupplementation also helps eliminate the possibility of any complications due to the indiscriminate use of painkillers”.

 

 

 

 

For more information please contact:

Atul Malikram

9827092823